Gotowa bibliografia na temat „Xanthines – therapeutic use”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Xanthines – therapeutic use”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Xanthines – therapeutic use"
Cazzola, Mario, Luigino Calzetta, Peter J. Barnes, Gerard J. Criner, Fernando J. Martinez, Alberto Papi i Maria Gabriella Matera. "Efficacy and safety profile of xanthines in COPD: a network meta-analysis". European Respiratory Review 27, nr 148 (2.05.2018): 180010. http://dx.doi.org/10.1183/16000617.0010-2018.
Pełny tekst źródłaCicero, Arrigo F. G., Federica Fogacci, Masanari Kuwabara i Claudio Borghi. "Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update". Medicina 57, nr 1 (10.01.2021): 58. http://dx.doi.org/10.3390/medicina57010058.
Pełny tekst źródłaCicero, Arrigo F. G., Federica Fogacci, Masanari Kuwabara i Claudio Borghi. "Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update". Medicina 57, nr 1 (10.01.2021): 58. http://dx.doi.org/10.3390/medicina57010058.
Pełny tekst źródłaAhmad, Saeed, Ejaz Mohiuddin, Syed Muhammad Ali Shah, Muhammad Akram, Muhammad Amjad, Jaweria Nisar, Muhammad Riaz, Naveed Munir i Ghulam Rasool. "Therapeutic Efficacy of Urinile Against Gouty Arthritis". Dose-Response 18, nr 4 (1.10.2020): 155932582094693. http://dx.doi.org/10.1177/1559325820946934.
Pełny tekst źródłaShen, Z., C. Colton, R. Yan, E. Polvent, V. Hingorani, S. Yan i L. T. Yeh. "POS1128 COMBINATION TREATMENT OF AR882, A NEW URAT1 INHIBITOR, AND XANTHINE OXIDASE INHIBITORS ALLOPURINOL OR FEBUXOSTAT: EFFECT ON URIC ACID, HYPOXANTHINE AND XANTHINE IN PLASMA OR SERUM AND URINE". Annals of the Rheumatic Diseases 80, Suppl 1 (19.05.2021): 843.2–843. http://dx.doi.org/10.1136/annrheumdis-2021-eular.1215.
Pełny tekst źródłaAouffen, M'hammed, Joanne Paquin, Eric De Grandpré, Réginald Nadeau i Mircea-Alexandru Mateescu. "Deglycosylated ceruloplasmin maintains its enzymatic, antioxidant, cardioprotective, and neuronoprotective properties". Biochemistry and Cell Biology 79, nr 4 (1.08.2001): 489–97. http://dx.doi.org/10.1139/o01-125.
Pełny tekst źródłaMunteanu, Mircea, Adrian Sturza, Adalbert Schiller i Romulus Timar. "Endothelial Dysfunction in Diabetes – Clasic Sources of Vascular Oxidative Stress (Nadph Oxidases, Enos Uncoupling and Xanthine Oxidase)". Romanian Journal of Diabetes Nutrition and Metabolic Diseases 20, nr 2 (1.06.2013): 149–55. http://dx.doi.org/10.2478/rjdnmd-2013-0019.
Pełny tekst źródłaMozgovaya, E., S. Bedina, A. Trofimenko, M. Mamus, S. Spitsina i I. Zborovskaya. "AB0061 ALTERATIONS OF XANTHINE OXIDOREDUCTASE ACTIVITY IN RED BLOOD CELLS AFTER GLUCOCORTICOID TREATMENT IN RHEUMATOID ARTHRITIS". Annals of the Rheumatic Diseases 80, Suppl 1 (19.05.2021): 1062.1–1062. http://dx.doi.org/10.1136/annrheumdis-2021-eular.3168.
Pełny tekst źródłaMokra, Daniela, i Juraj Mokry. "Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives?" International Journal of Molecular Sciences 22, nr 4 (16.02.2021): 1929. http://dx.doi.org/10.3390/ijms22041929.
Pełny tekst źródłaAuberval, Nathalie, Stéphanie Dal, William Bietiger, Elodie Seyfritz, Jean Peluso, Christian Muller, Minjie Zhao i in. "Oxidative Stress Type Influences the Properties of Antioxidants Containing Polyphenols in RINm5F Beta Cells". Evidence-Based Complementary and Alternative Medicine 2015 (2015): 1–11. http://dx.doi.org/10.1155/2015/859048.
Pełny tekst źródłaRozprawy doktorskie na temat "Xanthines – therapeutic use"
Duckworth, Megan Jane Medical Sciences Faculty of Medicine UNSW. "Characterisation of the xanthineguanine phosphoribosyltransferase of helicobacter pylori as a potential therapeutic target". Publisher:University of New South Wales. Medical Sciences, 2008. http://handle.unsw.edu.au/1959.4/43418.
Pełny tekst źródła"Evaluation of xanthine oxidase inhibitory and antioxidant activities of compounds from natural sources". 2005. http://library.cuhk.edu.hk/record=b5892399.
Pełny tekst źródłaThesis submitted in: September 2004.
Thesis (M.Phil.)--Chinese University of Hong Kong, 2005.
Includes bibliographical references (leaves 142-154).
Abstracts in English and Chinese.
Abstract --- p.i
Chinese Abstract --- p.iii
Acknowledgements --- p.v
Table of Contents --- p.vi
List of Abbreviations --- p.xii
List of Figures --- p.xv
List of Tables --- p.xix
Chapter Chapter 1 --- Introduction --- p.1
Chapter 1.1 --- Reactive oxygen species --- p.1
Chapter 1.1.1 --- Intracellular sources of ROS --- p.1
Chapter 1.1.2 --- Extracellular sources of ROS --- p.2
Chapter 1.1.3 --- Superoxide anion radicals --- p.2
Chapter 1.1.4 --- Hydrogen peroxide --- p.3
Chapter 1.1.5 --- Hydroxyl radicals --- p.3
Chapter 1.1.6 --- Singlet oxygen --- p.4
Chapter 1.1.7 --- Peroxyl radicals and peroxides --- p.4
Chapter 1.1.8 --- Damage of cellular structures by ROS --- p.5
Chapter 1.2 --- Antioxidative defence in the body --- p.6
Chapter 1.2.1 --- Antioxidant proteins --- p.6
Chapter 1.2.2 --- Antioxidant enzymes --- p.6
Chapter 1.2.3 --- Antioxidant compounds --- p.7
Chapter 1.2.3.1 --- Vitamin E --- p.8
Chapter 1.2.3.2 --- Vitamin C --- p.9
Chapter 1.2.3.3 --- Glutathione --- p.9
Chapter 1.2.3.4 --- Urate --- p.9
Chapter 1.2.3.4.1 --- Purine metabolism --- p.10
Chapter 1.2.3.4.2 --- Xanthine oxidase --- p.12
Chapter 1.2.4 --- Oxidative stress and antioxidant defence mechanisms in RBC --- p.12
Chapter 1.2.5 --- Oxidative stress and antioxidant defence mechanisms in LDL --- p.16
Chapter 1.3 --- Human diseases originated from pro-oxidant conditions --- p.16
Chapter 1.3.1 --- Atherosclerosis --- p.17
Chapter 1.3.2 --- Ischemia /reperfusion injury --- p.17
Chapter 1.3.3 --- Glucose-6-phosphate dehydrogenase deficiency --- p.18
Chapter 1.3.4 --- DNA mutation --- p.18
Chapter 1.3.5 --- Other pro-oxidant state related diseases --- p.19
Chapter 1.4 --- Hyperuricemia and gout: diseases originated from an extreme antioxidant condition --- p.19
Chapter 1.4.1 --- Inhibition of XOD as a treatment method for hyperuricemia --- p.20
Chapter 1.4.2 --- Relationship between ROS injury and hyperuricemia --- p.22
Chapter 1.5 --- Antioxidants in human nutrition --- p.23
Chapter 1.6 --- Chinese medicinal therapeutics --- p.23
Chapter 1.6.1 --- Rhubarb --- p.25
Chapter 1.6.2 --- Aloe --- p.26
Chapter 1.6.3 --- Ginger --- p.27
Chapter 1.6.4 --- Objectives of the project --- p.30
Chapter 1.6.5 --- Strategies applied to achieve the objectives of the present project --- p.30
Chapter Chapter 2 --- Materials and methods --- p.31
Chapter 2.1 --- XOD inhibition assay --- p.31
Chapter 2.1.1 --- Assay development --- p.31
Chapter 2.1.2 --- Dose-dependent study --- p.32
Chapter 2.1.3 --- Reversibility of the enzyme inhibition --- p.32
Chapter 2.1.4 --- Lineweaver-Burk plots --- p.33
Chapter 2.2 --- Lipid peroxidation inhibition assay of mouse liver microsomes --- p.34
Chapter 2.2.1 --- Preparation of mouse liver microsomes --- p.34
Chapter 2.2.2 --- Basis of assay --- p.34
Chapter 2.2.3 --- Assay procedures --- p.35
Chapter 2.3 --- AAPH-induced hemolysis inhibition assay --- p.36
Chapter 2.3.1 --- Preparation of RBC --- p.36
Chapter 2.3.2 --- Basis of assay --- p.36
Chapter 2.3.3 --- Assay procedures --- p.37
Chapter 2.4 --- Lipid peroxidation inhibition assay of RBC membrane --- p.38
Chapter 2.4.1 --- Preparation of RBC membrane --- p.38
Chapter 2.4.2 --- Basis of assay --- p.39
Chapter 2.4.3 --- Assay procedures --- p.40
Chapter 2.5 --- ATPase protection assay --- p.41
Chapter 2.5.1 --- Preparation of RBC membrane --- p.41
Chapter 2.5.2 --- Preparation of malachite green (MG) reagent --- p.41
Chapter 2.5.3 --- Basis of assay --- p.41
Chapter 2.5.4 --- Assay procedures --- p.42
Chapter 2.5.5 --- Determination of ATPase activities --- p.43
Chapter 2.5.6 --- Assay buffers --- p.43
Chapter 2.6 --- Sulfhydryl group protection assay --- p.44
Chapter 2.6.1 --- Preparation of RBC membrane --- p.44
Chapter 2.6.2 --- Basis of assay --- p.45
Chapter 2.6.3 --- Assay procedures --- p.45
Chapter 2.7 --- Lipid peroxidation inhibition assay of LDL by the AAPH method --- p.46
Chapter 2.7.1 --- Basis of assay --- p.46
Chapter 2.7.2 --- Assay procedures --- p.46
Chapter 2.8 --- Lipid peroxidation inhibition assay of LDL by the hemin method --- p.47
Chapter 2.8.1 --- Basis of assay --- p.47
Chapter 2.8.2 --- Assay procedures --- p.47
Chapter 2.9 --- Protein assay --- p.48
Chapter 2.10 --- Statistical analysis --- p.48
Chapter 2.11 --- Test compounds --- p.48
Chapter Chapter 3 --- Xanthine oxidase inhibition assay: results and discussion --- p.49
Chapter 3.1 --- Introduction --- p.49
Chapter 3.2 --- Results --- p.54
Chapter 3.3 --- Discussion --- p.59
Chapter Chapter 4 --- Lipid peroxidation inhibition in mouse liver microsomes: results and discussion --- p.64
Chapter 4.1 --- Introduction --- p.64
Chapter 4.2 --- Results --- p.64
Chapter 4.3 --- Discussion --- p.69
Chapter Chapter 5 --- Assays on protection of RBC from oxidative damage: results and discussion --- p.71
Chapter 5.1 --- Introduction --- p.71
Chapter 5.2 --- Results --- p.75
Chapter 5.2.1 --- AAPH-induced hemolysis inhibition assay --- p.75
Chapter 5.2.2 --- Lipid peroxidation inhibition assay of RBC membranes --- p.82
Chapter 5.2.3 --- Ca2+-ATPase protection assay --- p.88
Chapter 5.2.4 --- Na+/K+-ATPase protection assay --- p.95
Chapter 5.2.5 --- Sulfhydryl group protection assay --- p.100
Chapter 5.3 --- Discussion --- p.110
Chapter 5.3.1 --- AAPH-induced hemolysis inhibition assay --- p.110
Chapter 5.3.2 --- Lipid peroxidation inhibition assay of RBC membranes --- p.111
Chapter 5.3.3 --- Ca2+-ATPase protection assay --- p.113
Chapter 5.3.4 --- Na+/K+-ATPase protection assay --- p.114
Chapter 5.3.5 --- Sulfhydryl group protection assay --- p.115
Chapter 5.3.6 --- Chapter summary --- p.117
Chapter Chapter 6 --- Lipid peroxidation inhibition assay of LDL: results and discussion --- p.118
Chapter 6.1 --- Introduction --- p.118
Chapter 6.2 --- Results --- p.118
Chapter 6.3 --- Discussion --- p.134
Chapter Chapter 7 --- General discussion --- p.137
References --- p.142
Książki na temat "Xanthines – therapeutic use"
1946-, Barnes Peter J., red. The Mechanism of action of Xanthines in respiratory disease. London: Royal Society of Medicine Services, 1988.
Znajdź pełny tekst źródła(Editor), K. E. Andersson, i C.G.A. Persson (Editor), red. Anti-asthma Xanthines and Adenosine (Current clinical practice series). Elsevier, 1986.
Znajdź pełny tekst źródłaKarl-Erik, Andersson, Persson C. G. A i AB Draco, red. Anti-asthma xanthines and adenosine: Proceedings of a symposium in Copenhagen, February 22-23, 1985. Amsterdam: Excerpta Medica, 1985.
Znajdź pełny tekst źródła1944-, Costello J. F., Piper Priscilla J i Royal Society of Medicine (Great Britain). Respiratory Section., red. Methylxanthines and phosphodiesterase inhibitors in the treatment of airways disease: The proceedings of a meeting held by the Respiratory Section of the Royal Society of Medicine, London, November 1993. London: Parthenon Pub. Group, 1994.
Znajdź pełny tekst źródła